Date:
February 7, 2022
Issue #:
1643
Summary:
The FDA has approved adjunctive treatment with
Dartisla ODT (Edenbridge), a new orally disintegrating
tablet (ODT) formulation of the anticholinergic drug
glycopyrrolate, to reduce symptoms of a peptic ulcer.
Glycopyrrolate oral tablets (Robinul, Robinul Forte,
and generics) were approved for the same indication
in 1961.
Dartisla ODT (Edenbridge), a new orally disintegrating
tablet (ODT) formulation of the anticholinergic drug
glycopyrrolate, to reduce symptoms of a peptic ulcer.
Glycopyrrolate oral tablets (Robinul, Robinul Forte,
and generics) were approved for the same indication
in 1961.
